<DOC>
	<DOC>NCT02435303</DOC>
	<brief_summary>The purpose of this study is to determine whether Sildenafil is effective in the treatment of sustained pulmonary artery hypertension after corrected mitral valve disease.</brief_summary>
	<brief_title>Effect of Sildenafil for Sustained PAH After MV Surgery (SUPERIOR Trial)</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension, Pulmonary</mesh_term>
	<mesh_term>Heart Valve Diseases</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<criteria>New York Heart Association Functional class (NYHA Fc) ≥ 2 dyspnea which was sustained till one year after the previous mitral valve surgery (repair or replacement) TR Vmax ≥ 3.5m/s by echocardiography Normal left ventricle ejection fraction (EF ≥ 50%) Pulmonary vascular resistance ≥ 3 Wood Unit or diastolic pressure gradient ≥ 7mmHg by cardiac catheterization Other valve disease more than moderate degree (ex. aortic stenosis, aortic regurgitation) Liver cirrhosis Chronic renal failure with serum creatinine ≥ 1.7mg/dL Lung disease (ex. chronic obstructive pulmonary disease, Asthma) Thyroid dysfunction Other causes which can lead to pulmonary hypertension</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>